The gene MTS1 encodes p16 INK4 , an inhibitor of cyclindependent kinase 4, and is frequently deleted, mutated, or silenced by promoter methylation in melanoma cells and in the germline of familial melanoma patients. Although MTS1 may thus be the candidate melanoma suppressor gene that maps to chromosome 9p21, it is not clear how dysfunction at that locus temporally relates to melanoma progression. To further test its role in sporadic melanoma, the expression of p16 INK4 -protein and -mRNA was characterized in melanomas and melanocytic nevi by immunocytochemistry and in situ reverse transcriptasepolymerase chain reaction. Histologic tissue sections were immunolabeled with anti-p16 INK4 antibody for 108 melanocytic lesions, including common and atypical nevi, in situ melanomas, primary invasive melanomas, and metastatic tumors. A subset of the lesions was analyzed for expression of p16 INK4 -mRNA, employing forward and reverse intron-bridging primers for reverse transcriptase-polymerase chain reaction amplification of the transcript corresponding to exons 1 and 2 of MTS1.
C onvergent evidence from deletional mapping of melanoma tumor cells (Fountain et al, 1992) and genetic linkage analyses of melanoma kindreds (Cannon-Albright et al, 1992) has assigned a melanoma susceptibility locus (MLM) to chromosome 9p21. Positional cloning of the smallest region commonly deleted homozygously in melanoma cell lines later identified a gene, multiple tumor suppressor 1 (MTS1), as the candidate locus for MLM (Kamb et al, 1994a; Nobori et al, 1994) . The cDNA coding sequence of the expressed protein, p16 INK4 , had previously been identified with two-hybrid screening by investigators searching for natural inhibitors of the cyclin dependent kinases, which are molecules that enable passage of cells through G1-S cell cycle checkpoints (Serrano et al, 1993) . Subsequently, observations of segregating germline mutations in melanoma kindreds (Hussussian et al, 1994; Kamb et al, 1994b) and of somatic mutations in tumor cell lines of multiple histogenetic lineages (Smith-Sørensen and Hovig, 1996) have strongly supported the candidacy of MTS1 as a general Manuscript received September 19, 1997; revised December 29, 1997 
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Strong immunolabeling was detected in the melanocytes of common nevi and of nevi with architectural disorder and cytologic atypia. By digital image analysis, in contrast, labeling intensity decreased significantly and progressively in the melanocytes of in situ, invasive, and metastatic melanomas. Results from the in situ reverse transcriptase-polymerase chain reaction analysis were confirmatory, showing a strong signal in the melanocytic nevi but progressive signal attenuation with increasing stage of melanoma. These data indicate correlation between gradual loss of expression of the MTS1 locus and progression of melanoma, further supporting an emerging role for the gene in the malignant transformation of melanocytes. The failure to demonstrate reduced expression in nevi suggests either that these lesions are not an early stage in melanoma development, in contrast to prevailing assumptions, or that loss of p16 INK4 function is not an initiating event in melanocyte transformation. Key words: dysplastic nevi/melanoma/MTS1/nevi. J Invest Dermatol 110: [932] [933] [934] [935] [936] [937] [938] 1998 tumor suppressor locus for common cancers and more specifically for familial and sporadic melanoma.
Although inactivation of the MTS1 locus in cancer cells fits well conceptually with its candidate role as a tumor suppressor gene, given the apparently critical inhibitory function of p16 INK4 in cell cycle regulation, the temporal relationship of mutational lesions in the gene to the initiation and progression of melanoma has not been elucidated.
It is generally acknowledged that, in accordance with the theory of step-wise transformation, melanomas may evolve from melanocytic nevi as precursor lesions having undergone the first stage(s) in the neoplastic process (Clark et al, 1984; Elder et al, 1989) . Indeed, the spatial coexistence of incident melanomas with remnants of melanocytic nevi observed in histologic sections by numerous studies, tends to support this assertion (Skender-Kalnenas et al, 1995) , as do observations of malignant degeneration in congenital nevi and the direct correlation between total numbers of nevi and relative risk for melanoma in the case-control literature (reviewed by Piepkorn, 1994) . It is reasonable to expect, therefore, that the genome of nevus cells will harbor the molecular alterations necessary for the initiation of melanoma. Accordingly, we postulated that, given the strong case for MTS1 as a major locus contributing to the development of melanoma, abnormalities in expression of the gene at the mRNA or protein level will be demonstrable in the cells of melanocytic nevi. The studies presented herein represent a test of this specific hypothesis and of the more general hypothesis that inactivation of MTS1 correlates with progression of melanoma. Furthermore, in view of the suggestion that expression of p16 INK4 and the retinoblastoma gene product may be inversely correlated in some tumor systems (Otterson et al, 1994) , the status of RB1 expression was compared with that of p16 INK4 in a subset of the lesions. Our results extend those of Reed et al (1995) and Talve et al (1997) , who immunolabeled melanocytic lesions with antibodies against p16 INK4 . In qualitative analyses, Reed et al (1995) observed decreased labeling in invasive and metastatic melanomas, but uniform labeling in melanocytic nevi and in situ melanomas, suggesting that loss of p16 INK4 expression may not be an initiating event in transformation. Talve et al (1997) confirmed both the uniform labeling of nevus cells and the loss of expression with melanoma progression, but they observed decreased expression in melanoma in situ. Neither study specifically evaluated atypical (dysplastic) nevi. As reported herein, our observations support the findings of Talve et al (1997) that p16 INK4 immunostaining is reduced in some melanomas in situ, which is consistent with the locus being an early target in melanoma initiation. The original aspects of our report include: quantitation of p16 INK4 immunostains of melanocytic tumors by digital image analysis; the observation of normal levels of p16 INK4 immunolabeling in atypical nevi, which is notable because such lesions are purported to be melanoma precursor lesions; the lack of an apparent inverse correlation between p16 INK4 and RB1 expression in melanomas; and the finding that expression levels of p16 INK4 mRNA by in situ reverse transcriptase polymerase chain reaction (RT-PCR) correlate with reductions in p16 INK4 immunolabeling during melanoma progression.
MATERIALS AND METHODS
Cell culture Primary keratinocyte and melanocyte cultures were established from human neonatal foreskins (Fligiel et al, 1992; Piepkorn et al, 1994) and grown in complete keratinocyte growth medium (cKGM; Clonetics, San Diego, CA), or complete melanocyte growth medium (cMGM; Clonetics), respectively. The cells were used at the second to fourth passage levels. Human melanoma cell lines HTB 66, HTB 70, and HTB 71, and a human breast cancer cell line, MCF7, were obtained from the American Type Culture Collection (Rockville, MD) and grown as monolayered cultures in Dulbecco's minimum essential medium (BioWhittaker, Walkersville, MD), containing 10% fetal bovine serum (Intergen, Purchase, NY). Two days prior to the immunolocalization experiments, cells of each cell type were subcultured into LabTek chamber slides (Nunc, Naperville, IL) at 1-2 ϫ 10 4 cells per cm 2 .
Tissue samples Five micrometer recuts were prepared from formalin-fixed, paraffin-embedded tissues retrieved from the pathology files of the University of Washington Medical Center. The specimens consisted of 108 melanocytic lesions, including common and atypical nevi, in situ melanomas, primary invasive melanomas, and metastatic tumors. The original diagnoses were confirmed by review of the hematoxylin and eosin stained sections using standard diagnostic criteria for each lesion type as applied by one of us (MP). The diagnoses of the metastatic lesions were corroborated by review of the routine histology and immunoperoxidase studies with markers for S100 protein and/or HMB-45.
Western immunoblotting The specificities of the anti-p16 INK4 mouse monoclonal antibody, G175-405, and the anti-retinoblastoma protein (RB1) monoclonal antibody, G3-245 (both purchased from PharMingen, San Diego, CA), were established by western immunoblotting of cell extracts from human neonatal keratinocyte and melanocyte cultures, established melanoma cell lines, and a breast cancer cell line (MCF 7). Cell layers in exponential growth were washed twice with chilled phosphate-buffered saline and scraped into 300 µl of cold lysis buffer (50 mM Tris HCl, 0.25 M NaCl, 0.1% Triton X-100, 1.0 mM ethylenediaminetetraacetic acid, 50 mM NaF, 1.0 mM dithiothreitol, 0.1 mM Na 3 VO 4 ) with 0.1 mM phenylmethylsulfonyl fluoride, 1 µg leupeptin per ml, 10 µg soybean trypsin inhibitor per ml, 10 µg N-tosyl-L-phenylalanine chloromethyl ketone per ml, 10 µg Na-p-tosyl-L-lysine chloromethyl ketone per ml, and 1 µg aprotinin per ml (Tam et al, 1994) . Following incubation on ice for 30 min, the cells were pooled and homogenized, and the homogenates were centrifuged for 5 min at 300 ϫ g at 4°C. The protein concentrations in the supernatants were measured with the Bio-Rad protein assay (Bio-Rad Laboratories, Richmond, CA), and the supernatants were concentrated into sample buffer. Twenty-five to 50 µg of total protein from each cell extract were resolved electrophoretically by nonreducing sodium dodecyl sulfatepolyacrylamide gel electrophoresis, along with molecular-weight markers (Amersham, Arlington Heights, IL; Gibco BRL, Gaithersburg, MD; and Novex, San Diego, CA) using 12% and 7.5% acrylamide gels. The gels were transferred for 1 h at 100 V to nitrocellulose sheets (BioRad), which were blocked with Tris-saline (50 mM Tris base, 0.15 M NaCl, pH 7.4) containing 0.25% gelatin/ 0.05% NP-40 (Sigma, St. Louis, MO)/5 mM ethylenediaminetetraacetic acid for 1 h at room temperature and incubated with a 1:250 dilution of the primary anti-p16 INK4 antibody or anti-RB1 antibody stock solution (0.5 mg per ml) overnight at 4°C. The blots were washed with buffer three times and incubated with 1:1000 secondary, horse anti-mouse antibody conjugated to horseradish peroxidase (Vector Laboratories, Burlingame, CA) for 60 min at room temperature. Following a wash with 0.25% gelatin/0.05% NP-40/0.4% sarcosyl in Tris-saline, immunolocalization was by enhanced chemiluminescence according to the manufacturer (ECL, Amersham) with 3 to 40 s exposure times (see Fig 1) .
Immunostaining In preliminary analyses, the G175-405 and G3-245 antibodies were determined to specifically detect p16 INK4 and RB1, respectively, in frozen and formalin-fixed tissue samples. Antibody localization was by avidinbiotin peroxidase staining of histologic sections from benign and malignant melanocytic lesions and by fluorescein immunofluorescence of cultured keratinocytes, melanocytes, melanoma cells, and breast cancer cells grown on slide chambers. For immunohistochemistry, 5 µm paraffin sections of formalin-fixed tissue were deparaffinized and rehydrated through a graded series of ethanol. After blocking of endogenous peroxidase activity with 0.3% hydrogen peroxide, the sections for RB1 immunolabeling were processed in a 750 Watt microwave oven at maximum power, twice, for 4 min, to enhance antigen detection. Sections were blocked with Tris-saline, pH 7.5, containing serum and 0.1% bovine serum albumin, and incubated with either a 1:100 or a 1:150 dilution of the primary anti-p16 INK4 or anti-RB1 antibody, or buffer or preimmune mouse serum as negative controls, overnight at 4°C. Following three buffer washes of the sections, the secondary biotinylated horse anti-mouse antibody conjugated to biotin (1:200, Vector Laboratories) and peroxidase-labeled streptavidin (1:50, Vector Laboratories) were sequentially applied for 30 min at room temperature, and reaction product was visualized with hydrogen peroxide and 3Ј-amino 9Ј-ethylcarbazole (AEC, Sigma) as chromogenic substrate.
For subcellular localization of immunofluorescence labeled product, the cell layers on the chamber slides were rinsed in phosphate-buffered saline, fixed in methanol at -20°C for 2 min, rinsed, blocked with serum, and reacted with the anti-p16 INK4 antibody (1:100) or the anti-RB1 antibody (1:150) overnight at 4°C. For anti-p16 labeling, the secondary antibody (horse anti-mouse conjugated to fluoroscein isothiocyanate, Vector Laboratories), diluted at 1:100, was applied for 30 min. The anti-RB1 exposed slides were sequentially incubated with the secondary biotinylated horse anti-mouse antibody (1:200) and with Texas Red-conjugated streptavidin (1:1000, Vector Laboratories). The slide chambers were washed, mounted with Vectashield (Vector Laboratories), and viewed using a Zeiss Universal microscope equipped with epi-illumination or with a Bio-Rad MRC-600 laser scanning confocal microscope.
Image analysis Immunoperoxidase labeling intensities were quantitated with an image analysis system based on Optimas 4.0 image analysis software (Optimas, Bothell, WA), using a World Video CCD camera connected to a Leitz Laborlux D microscope (Leitz, Wetzlar, Germany) with a stabilized power supply and a VisionPlus-AT CFG frame grabber (Imaging Technologies, Woburn, MA). Except as noted, a random sampling strategy was followed. After properly decalibrating the system (Hugo et al, 1996) , representative fields were captured (ϫ20 objective) and corrected for uneven illumination. Cells underlying computer-generated random coordinates in each field were manually outlined and the average inverse log of the inverse gray value (which is proportional to the amount of light absorbing material in the light path) was computed for all pixels in each cell. Twenty cells were analyzed in each of 10 fields for each lesion. Data were exported to Excel (Microsoft, Redmond, WA) for analysis and graphical display. For in situ melanomas, slides were analyzed by manually selecting representative neoplastic melanocytes because the pagetoid distribution of these cells within the epidermal keratinocytes did not lend itself to random sampling from computer generated coordinates. For comparison, slides of other lesions were also analyzed using manual sampling. Average cell labeling was similar for the two sampling strategies but the randomly selected cells generally exhibited greater variability of staining between cells (not shown). Variability in staining was reduced by batch processing of those lesions for which labeling intensities were compared.
In situ RT-PCR A four-step protocol described by Nuovo (1994) was used to localize p16 INK4 -specific mRNA sequences within melanocytic lesions. Five micrometer thick paraffin-sections of formalin-fixed tissue were transferred to silane-coated slides, dewaxed, and protease digested to facilitate reagent penetration into the cells. The sections were incubated with pepsin (Sigma) at 2 mg per ml for varying incubations (15-90 min), as adjusted for the estimated lengths of time the tissues had been fixed in formalin. The RT and PCR steps were performed in a GeneAmp In Situ PCR System 1000 (Perkin-Elmer, Foster City, CA). After digestion with 10 U per tissue section of RNase-free DNase (Boehringer Mannheim, Indianapolis, IN), to block amplification of genomic DNA, the mRNA was reverse-transcribed to generate cDNA templates by SuperScript S2 Reverse Transcriptase (BRL, Gaithersburg, MD), according to the manufacturer's specifications. For PCR amplification of the cDNA and direct labeling of the amplified product, the following mixture was used: 2.5 mM MgCl 2 , 200 µM cocktail of dNTP, 10 µM digoxigenin-11-2Јdeoxyuridine-5Ј-triphosphate (Boehringer Mannheim), 0.8 µM forward and reverse primers (see Table I ), 0.08% bovine serum albumin (Sigma), and 2.5 U Taq DNA Polymerase (BRL). Synchronized ''hot start'' PCR was achieved using the temperature-sensitive Taq-blocking monoclonal antibody supplied by Clontech (Palo Alto, CA) (Kellog et al, 1994; Martínez et al, 1995) . A 25 µl aliquot of solution was applied to each section and 20 thermal cycles proved adequate to obtain crisp staining. Detection of the digoxigenin-labeled product utilized a kit from Boehringer Mannheim, which employed an anti-digoxigenin alkaline phosphatase-conjugated antibody, followed by exposure to nitroblue tetrazolium chloride and 5-bromo-chloro-3-indolyl-phosphate. The darkpurple reaction product was visualized by bright-field microscopy.
Negative (DNase-digestion, no reverse transcriptase) and positive controls (no DNase-digestion) were performed on the same glass slide with each test. Before the final in situ RT-PCR analyses, all parameters for the PCR reaction, including MgCl 2 concentration, pH, and annealing temperature, had been optimized by standard solution phase PCR.
RESULTS

Specificities of the anti-p16 INK4 , G175-405, and the anti-RB1, G3-245, monoclonal antibodies established by western immunoblotting
The specificities of the p16 INK4 and RB1 antibodies were evaluated by western immunoblotting of cell extracts from human neonatal keratinocyte and melanocyte cultures, established melanoma cell lines, and a breast cancer cell line (MCF 7). A full-length recombinant bacterially produced GST-p16 INK4 fusion protein was used as immunogen for preparation of the anti-p16 INK4 antibody (Serrano et al, 1993) . A major band migrating with an apparent mass of µ16 kDa was detected from keratinocyte, melanocyte, and HTB 66 cell extracts (Fig 1) . The absence of significant bands from p16 INK4 -negative cell lines HTB 70, HTB 71, and MCF 7 indicates no nonspecific cross-reactivity with other cellular proteins (Fig 1) . G3-245, the anti-RB1 antibody, recognizes an epitope corresponding to amino acid residues 300-380 of the human retinoblastoma protein (pp110-114 RB1) (De Caprio et al, 1988) . Major bands at µ110-116 kDa (Riley et al, 1994) were strongly labeled in HTB 70, HTB 71, and MCF 7 extracts and more weakly labeled in extracts of melanocytes, keratinocytes, and HTB 66 cells (not shown). Labeling intensities were greater in the p16 INK4 -negative cell lines (HTB 70, HTB 71, and MCF 7), suggesting that RB1 is overexpressed as a consequence of upregulated cyclin D-CDK4 activity.
Subcellular localization of immunolabeled p16 INK4 and RB1 imaged by confocal microscopy For localization of p16 INK4
and RB1 proteins by immunofluorescence, cultures of human neonatal keratinocytes and melanocytes, established melanoma cell lines, and a breast cancer cell line (MCF 7) were immunolabeled with anti-p16 INK4 or anti-RB1 antibody and detected with fluoroscein isothiocyanate-or Texas Red-conjugated secondary antibodies. Subcellular localization was imaged by scanning laser confocal microscopy, and the results for the HTB 66 and HTB 70 cell lines are illustrated in Fig 2. Immunolabeled p16 INK4 displayed diffusely granular cytoplasmic fluorescence, with random perinuclear and focal granular nuclear staining, in melanocytes, keratinocytes, and the HTB 66 melanoma cell line (Fig 2A) . In contrast, there was no detectable immunolabeling of the p16 INK4 -negative cell lines MCF 7, HTB 71, and HTB 70 (Fig 2C) . Reed et al (1995) also reported combined cytoplasmic and nuclear staining by immunoperoxidase labeling of melanocytic cells with a polyclonal anti-p16 INK4 antibody.
Immunolabeling with anti-RB1 demonstrated granular nuclear, but minimal cytoplasmic, staining for all tested cell types, as illustrated in Fig 2(B, D) for HTB 66 and HTB 70, respectively.
Immunolabeling patterns for p16 INK4 and RB1 in melanocytic lesions are distinct Immunoperoxidase staining for p16 INK4 and RB1 was performed on histologic sections from benign and malignant melanocytic lesions. Keratinocytes, which were found in these studies to strongly express p16 INK4 , served as positive internal controls for those lesions present within skin. The slides were reviewed independently by two observers; the semiquantitative visual scores are summarized in Table II . Uniform labeling in at least two-thirds of melanocytic cells was detected in 86% of common and atypical melanocytic nevi (Fig 3A, B) . Labeling at this proportion of the cell populations decreased to 72% for melanomas in situ (Fig 3C) and to 59% for primary invasive melanomas, whereas only 49% of metastatic tumors expressed p16 INK4 at this level (Fig 3D) . p16 INK4 labeling thus attenuated with advancement in tumor stage, as referenced to the consistent staining of keratinocytes as the internal control. Because it has been suggested that p16 INK4 and RB1 expression may be inversely correlated in some tumor systems (Otterson et al, 1994) , and because nuclear expression of RB1 has been reported to be higher in melanomas than in nevi (Saenz-Santamaria et al, 1995) , immunohistochemistry for RB1 was also performed in about one-third of the melanocytic lesions that had been immunolabeled for p16 INK4 (Table III) . No inverse correlation between the RB1 status and p16 INK4 expression was observed in this series. Strong labeling for p16 INK4 and RB1 was detected in 54% of the melanocytic lesions, and only 7% strongly expressed p16 INK4 when RB1 staining was minimal to negative. A similar absence of inverse correlation between the expression levels of p16 INK4 and RB1 by immunolabeling has been reported in nonmelanoma malignancies (Geradts et al, 1995) .
Intensity of p16 INK4 immunolabeling quantitatively attenuates with melanoma progression
Histologic slides immunostained for p16 INK4 were quantitated for labeling intensity with the Optimas image analysis system (Materials and Methods). The results are presented in Fig 4. In seven cases of melanomas with coexisting melanocytic nevi, the nevus cells strongly expressed p16 INK4 , whereas adjacent melanoma cells consistently displayed reduced staining intensity, and the keratinocytes expressed p16 INK4 at an intermediate level (Fig 4A) . Quantitative comparisons of the levels of p16 INK4 Figure 4 . p16 INK4 labeling intensity correlates with disease progression in melanoma. (A) p16 INK4 immunostaining intensities in epidermal keratinocytes, nevus cells, and melanoma cells were quantitated in histologic sections of seven different melanomas with coexisting nevi. For this analysis, the cells were manually selected. Data are shown as means Ϯ SEM for 200 cells. The labeling for p16 INK4 was consistently greater in nevus cells than in melanoma cells, and keratinocytes expressed p16 INK4 at an intermediate level. The differences between the means for the nevus and melanoma cells, combined for the seven pairs of data, are significant at p Ͻ 10 -4 by Student's t test. (B) Quantitation of immunostaining intensities in common and atypical nevi, melanomas in situ, primary invasive melanomas, and metastatic melanomas indicated strong expression of p16 INK4 in nevus cells and progressive decrease in label intensity with advancement in melanoma stage. Each bar represents the mean with 95% confidence interval of the labeling intensity of 200 cells selected by computer randomization from each lesion (see Materials and Methods) . Differences between the means for the common and atypical nevi are not statistically significant in this series, whereas the mean labeling intensities for melanoma in situ, invasive melanoma, and metastatic melanoma are significantly decreased compared with the mean for common nevi at p Ͻ 10 -4 by the Mann-Whitney U test. AN, atypical nevi; MIS, melanoma in situ; IM, invasive melanoma; MM, metastatic melanoma. Numbers of lesions are given in parentheses. a 1ϩ, less than one-third of melanocytic cells with uniform labeling; 2ϩ, one-to twothirds with uniform labeling; 3ϩ, at least two-thirds with uniform labeling. expression between common nevi, atypical nevi, melanomas in situ, primary invasive melanomas, and metastatic tumors indicated that p16 INK4 labeling intensity was strong in both the common and the atypical nevi, but attenuated progressively with advancement in tumor stage from in situ to metastatic melanoma (Fig 4B) .
Expression levels of p16 INK4 mRNA by in situ RT-PCR correlate with immunolabeling of p16 INK4 in melanocytic lesions Results from p16 INK4 immunolabeling were correlated with expression of p16 INK4 mRNA by in situ RT-PCR in approximately two-thirds of the melanocytic lesions (Table IV) . As with p16 INK4 immunolabeling, uniform expression of p16 INK4 -mRNA in a majority of the lesional melanocytic cells was detected in 18 of 23 (78%) common nevi that were examined, whereas expression at this level was observed in only six of 13 (46%) metastatic melanomas. The same lesions that showed low levels of protein labeling also expressed low amounts of p16 INK4 mRNA. Figure 5 illustrates the correlation between p16 INK4 immunolabeling and in situ RT-PCR in a case of superficial spreading melanoma. Overall, therefore, expression of p16 INK4 -protein and -mRNA in the 61 melanocytic lesions was concordant.
DISCUSSION
With these studies we have further evaluated the chromosome 9p21 locus, MTS1, as a candidate melanoma suppressor gene in a series of melanocytic lesions ranging from common nevi to metastatic melanoma. Immunolabeling of the expressed product, p16 INK4 , was correlated with analysis for p16 INK4 -mRNA by in situ RT-PCR with intron bridging primers and was compared with the immunolabeling status of RB1 in a representative subset of the lesions. The specificity of the p16 INK4 monoclonal antibody used for these purposes was corroborated by western immunoblotting of normal and transformed cell lines, including cells that do not express p16 INK4 (Fig 1) . Imaging of immunolabeled p16 INK4 by scanning laser confocal microscopy indicated that the protein is distributed to both the cytoplasms and the nuclei of normal and transformed melanocytes, in agreement with previous studies (Reed et al, 1995; Talve et al, 1997) , whereas RB1 was generally restricted to the nuclei (Fig 2) . No inverse correlation was apparent between the expression status of RB1 and p16 INK4 in these melanocytic lesions, contrary to expectations. Moreover, expression levels of p16 INK4protein and -mRNA in the nevomelanocytes of both common and atypical (dysplastic) nevi were not appreciably reduced. The transformed melanocytes of in situ, invasive, and metastatic melanomas, however, expressed p16 INK4 at significantly reduced levels by quantitative immunolabeling (Fig 4) , and an inverse correlation between p16 INK4 -protein and -mRNA levels and stage of the disease was observed, suggesting a role in the progression of melanoma.
Current understanding of neoplastic transformation invokes a stepwise pathway of progression to the fully malignant phenotype in tumor systems. This paradigm has been best characterized from studies of colon carcinoma cells (Powell et al, 1992) , but it may be generally applicable to many tumor systems, including that of melanoma (Elder et al, 1989) . Under the general model of melanoma progression, certain morphologic variants of melanocytic nevi have been incorporated as a first stage in carcinogenesis (Clark et al, 1984; Elder et al, 1989) . It is reasonable, therefore, to evaluate these putative precursor lesions for molecular alterations in the search for the events initiating transformation to melanoma.
The familial melanoma locus, MTS1, is a plausible target for a genetic lesion that initiates transformation. Data acquired from the genetic linkage of MTS1 markers at chromosome 9p21 to familial melanoma (Cannon-Albright et al, 1992) and from deletional mapping of melanoma tumors, which has shown chromosome 9p21 to be the most common genomic target for loss of heterozygosity and homozygous deletions in some analyses (Fountain et al, 1992) , are compatible with a role in tumor initiation. The alternative hypothesis of a more distal event in progression is counterintuitive, unless another covert initiating mutation depends on coordinate, distal inactivation of MTS1 for clinically overt disease in the families that were used for genetic linkage.
Our data are consistent with an important role for p16 INK4 inactivation during melanoma progression, regardless of the actual chronology. A perceptible decrease in the expression level of p16 INK4protein and -mRNA was observed in melanomas, commencing with the first clearly recognizable stage of the disease, that of the in situ lesions (Fig 4B) . Moreover, there was attenuation in the expression level with advancing stage of melanoma. Whereas these results do not of course discriminate between an initiating or more distal event, decreased expression of MTS1 during tumor progression is obviously not an all-or-none event, but rather a graded process. This suggests a stoichiometric mechanism for carcinogenesis, such as one where a molar deficiency of p16 INK4 has the net effect of upregulating the activation of CDK4 by cyclin D through loss of competitive inhibition. There would then be more inactivation by phosphorylation of RB1, the target substrate of CDK4, forcing the equilibrium in the direction of unregulated cell growth, thereby fostering malignant transformation. As suggested by our data, the regulatory effects of p16 INK4 at the late G1 cell cycle checkpoint may be progressively lost as the expression of the gene product attenuates with advancing stage of melanoma. It must be noted, however, that p16 INK4 -protein and -mRNA levels were normal in some fully evolved melanomas in this series, although abnormal p16 INK4 function due to intragenic point mutations could not be ruled out. A role for other parallel molecular pathways of oncogenesis is suggested in these cases.
In the report of Reed et al (1995) , qualitatively uniform labeling with a polyclonal antibody was observed in 100% of common and atypical nevi and in situ melanomas, but there was reduced labeling of primary invasive and metastatic tumors. The results of Talve et al (1997) using a monoclonal antibody were similar, although some melanomas in situ failed to immunolabel for p16 INK4 . Taken together with our corroborating data from quantitative immunolabeling with a monoclonal antibody and from in situ RT-PCR with specific primers for p16 INK4 -mRNA, it can be reasonably concluded that expression of p16 INK4 is progressively lost with advancement in tumor stage in many cases of melanoma. Moreover, this study and those of both Reed et al (1995) and Talve et al (1997) are concordant for apparently normal expression levels in nevi. In support of the results of Talve et al (1997) , however, we observed that mean expression levels are significantly decreased in melanomas in situ. This difference in the results could be methodologic in nature or could reflect variations in the composition of the samples. Neither of the other studies specifically evaluated atypical nevi, which as described herein express normal levels of p16 INK4 protein and mRNA. Whereas Reed et al (1995) concluded from their data with nevi and melanomas in situ that inactivation of MTS1 is not an initiating event, our observations and those of Talve et al (1997) would be consistent with a more proximal stage for MTS1 inactivation if melanocytic nevi are set aside as formal precursor lesions.
Whereas the precise nature of melanocytic nevi and their biologic function, if any, remain largely unknown, a precursor relationship with melanoma has been widely accepted from several lines of evidence (Skender-Kalnenas et al, 1995) . If the validity of this conventional model is assumed, such that nevi constitute a proximate morphologic stage in melanoma carcinogenesis (Clark et al, 1984; Elder et al, 1989) , then our data showing apparently nominal levels of p16 INK4 -protein and -mRNA in common and atypical nevi would indicate that loss of its expression is not an initiating event. The alternative interpretation is that nevi may not be a first step in malignant transformation, which could accommodate an early, rate limiting role for MTS1 in the process. There in fact exist empiric observations inconsistent with the position of melanocytic nevi as proximate precursor lesions to melanoma. Among these are the generally low expression levels of proliferation markers in nevus cells (Saenz-Santamaria et al, 1994) , the upregulation of apoptocytic factors in nevi (Kanik et al, 1995) , and the difficulty in culturing the cells. Such observations, taken together with those reported here, invoke the question of the pathophysiologic role of nevi. One reasonable view is that the spatial association of nevi with melanomas reflects pleiotropic, and divergent, processes sharing a common causation, rather than sequential phases in a continuous, linear progression. This hypothesis, which would account for many of the empiric data, suggests a biologic function for nevi as an adaptive or protective response to melanocytic injury.
